Search Results for: macular degeneration

Japan Aiming For a Commanding Position on New Stem Cells

Masayo-Takahashi-ISSCR-300x239

Stem cell technology is poised to wow the world with biomedical advances in the coming decades and Japan wants to lead the way. They want to forge ahead particularly with applications that focus on a relatively new kind of stem cells called induced pluripotent stem cells or iPS cells. Japanese researcher, Shinya Yamanaka, first reported production

Japan Aiming For a Commanding Position on New Stem Cells Read More »

FDA & Japanese Health Ministry (厚生労働省) To Develop iPS cell clinical rules

FDA3-300x2581

In a rare sign of stem cell international regulatory unity, the Japanese Health Ministry (厚生労働省) and the US FDA have agreed to develop a joint, unified regulatory framework for clinical studies of human iPS cells for use in treating retinal diseases. Presumably the rules would also guide clinical use of iPS cells to treat other

FDA & Japanese Health Ministry (厚生労働省) To Develop iPS cell clinical rules Read More »

Striking improvement in vision in one ACT trial participant

advanced-cell-technology

Advanced Cell Technology (ACT) has confirmed that one of the patient in a clinical trial that it is running for treatment of macular degeneration, the leading cause of blindness worldwide, has shown a striking improvement in vision. The patient reportedly had 20/400 vision prior to treatment and now has 20/40 vision after treatment. ACT uses an

Striking improvement in vision in one ACT trial participant Read More »

Putting the IP in iPS cells: patent war looming?

war

Will intellectual property (IP) wars over patent rights to one of the most exciting new stem cell technologies hold back getting novel therapies to patients such as IPS cells? Unfortunately, it’s very possible. Induced pluripotent stem (iPS) cells are very cool stem cells made from non-stem cells through a process called cellular reprogramming. iPS  cells

Putting the IP in iPS cells: patent war looming? Read More »

Interview with Gary Rabin of Advanced Cell Technology (ACT)

Gary-Rabin-headshot-formatted-5.25

One of the more exciting stem cell biotechs out there today is Advanced Cell Technology (ACT). At this time ACT has the only two ES cell-based FDA-approved clinical trials ongoing and so far they have looked quite promising in terms of preliminary safety data. However, ACT has much more in the pipeline including potentially iPS

Interview with Gary Rabin of Advanced Cell Technology (ACT) Read More »